| First Author | Heydemann A | Year | 2004 |
| Journal | J Mol Cell Cardiol | Volume | 36 |
| Issue | 2 | Pages | 213-23 |
| PubMed ID | 14871549 | Mgi Jnum | J:101900 |
| Mgi Id | MGI:3605904 | Doi | 10.1016/j.yjmcc.2003.09.020 |
| Citation | Heydemann A, et al. (2004) Functional nitric oxide synthase mislocalization in cardiomyopathy. J Mol Cell Cardiol 36(2):213-23 |
| abstractText | Mutations in the dystrophin glycoprotein complex, and in particular the sarcoglycan subcomplex, lead to cardiomyopathy and muscular dystrophy. Mice with mutations in gamma-sarcoglycan or delta-sarcoglycan develop cardiomyopathy that is characterized by focal regions of tissue damage. These focally damaged regions constitute 0-5% of cardiac tissue. In cardiomyopathy arising from sarcoglycan mutations, we found that endothelial nitric oxide synthase (eNOS) was significantly increased in focally damaged cardiac myocytes. In addition, we noted that nitric oxide (NO) was also increased in regions of tissue damage and altered membrane permeability. In sarcoglycan mutant mice, regionally increased cardiac NO was associated with hypersensitivity to carbachol and decreased sensitivity to adrenergic stimulation. Inhibition of NO production in sarcoglycan mutant mice was associated with improved recovery after carbachol and isoproterenol infusion. These data provide a mechanism where regional, focal cardiac damage creates pathologic gradients of NO. Moreover, inhibition of nitric oxide synthase corrects defects that arise from pathologic NO gradients. |
